TIDMAZN

RNS Number : 2133S

AstraZeneca PLC

08 March 2023

8 March 2023 11:01 GMT

Transactions by Persons Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 4 March 2023, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.

 
 PDMR              Position                Ordinary          Ordinary          Award price 
                                            Shares granted    Shares granted    per Ordinary 
                                            under the         under the         Share 
                                            AZDBP             AZPSP 
                   Executive Director 
                    and Chief Executive 
 Pascal Soriot      Officer                         14,448            85,808       GBP108.21 
                  ----------------------  ----------------  ----------------  -------------- 
                   Executive Director 
                    and Chief Financial 
 Aradhana Sarin     Officer                          7,403            38,046       GBP108.21 
                  ----------------------  ----------------  ----------------  -------------- 
 

The AZDBP award represents the portion of each PDMR's annual bonus for 2022 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance. The performance measures will be assessed over a three-year performance period (1 January 2023 to 31 December 2025). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2022, which is available on the Company's website at www.astrazeneca.com/annualreport202 2 .

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                          Pascal Soriot 
      ----------------------------  ------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------- 
 a)    Position/status               Chief Executive Officer 
      ----------------------------  ------------------------------------- 
 b)    Initial notification          Initial notification 
        /Amendment 
      ----------------------------  ------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------- 
 a)    Name                          AstraZeneca PLC 
      ----------------------------  ------------------------------------- 
 b)    LEI                           PY6ZZQWO2IZFZC3IOL08 
      ----------------------------  ------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4i    for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------- 
 a)    Description of the            Ordinary Shares of US$0.25 each in 
        financial instrument,         AstraZeneca PLC 
        type of instrument 
 
        Identification code           GB0009895292 
      ----------------------------  ------------------------------------- 
 b)    Nature of the transaction     Grants of share awards under the 
                                      AstraZeneca Performance Share Plan 
                                      and the AstraZeneca Deferred Bonus 
                                      Plan 
      ----------------------------  ------------------------------------- 
 c)    Price(s) and volume(s)          Price(s)     Volume(s) 
                                        GBP108.21    100,256 
                                                    ---------- 
      ----------------------------  ------------------------------------- 
 d)    Aggregated information        Not applicable - single transaction 
 
        - Aggregated volume 
        - Price 
      ----------------------------  ------------------------------------- 
 e)    Date of the transaction       4 March 2023 
      ----------------------------  ------------------------------------- 
 f)    Place of the transaction      Outside a trading venue 
      ----------------------------  ------------------------------------- 
 
 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                             Aradhana Sarin 
      -------------------------------  ------------------------------------ 
       Reason for the notification 
  2 
      --------------------------------------------------------------------- 
 a)    Position/status                  Chief Financial Officer 
      -------------------------------  ------------------------------------ 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  ------------------------------------ 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------- 
 a)    Name                             AstraZeneca PLC 
      -------------------------------  ------------------------------------ 
 b)    LEI                              PY6ZZQWO2IZFZC3IOL08 
      -------------------------------  ------------------------------------ 
       Details of the transaction(s): section to be repeated 
  4i    for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------- 
 a)    Description of the               Ordinary Shares of US$0.25 each in 
        financial instrument,            AstraZeneca PLC 
        type of instrument 
 
        Identification code              GB0009895292 
      -------------------------------  ------------------------------------ 
 b)    Nature of the transaction        Grants of share awards under the 
                                         AstraZeneca Performance Share Plan 
                                         and the AstraZeneca Deferred Bonus 
                                         Plan 
      -------------------------------  ------------------------------------ 
 c)    Price(s) and volume(s)             Price(s)     Volume(s) 
                                            GBP108.21      45,449 
                                                       ---------- 
      -------------------------------  ------------------------------------ 
 d)    Aggregated information           Not applicable - single transaction 
 
        - Aggregated volume 
        - Price 
      -------------------------------  ------------------------------------ 
 e)    Date of the transaction          4 March 2023 
      -------------------------------  ------------------------------------ 
 f)    Place of the transaction         Outside a trading venue 
      -------------------------------  ------------------------------------ 
 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUBSWROKUORAR

(END) Dow Jones Newswires

March 08, 2023 06:01 ET (11:01 GMT)

Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Astrazeneca